CLYM Climb Bio, Inc. Loading...

Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
17:51
Jul 14
__con_ Stock & Crypto Analyst
The author is compiling a list of follower-requested stocks for future review without expressing any current positions or trade ideas.
CLYM
LOW
07:31
Jul 05
__con_ Stock & Crypto Analyst
The author lists 23 stocks he plans to review after receiving suggestions from followers, with no current position or directional view expressed.
CLYM
LOW
19:19
Feb 04
A May MD Biotech investor
Long CLYM — LLY's nondepleting mAb mechanism is a positive clinical readthrough for CLYM, suggesting CLYM's approach aligns favorably with this finding.
CLYM 1ST
MED

About CLYM Analyst Coverage

Buzzberg tracks CLYM (Climb Bio, Inc.) across 2 sources. 1 bullish vs 0 bearish calls from 2 analysts. Sentiment: predominantly bullish (33%). 3 total trade ideas tracked. Past 7 days: 1 watch. Latest voices: __con_, A May MD.